The 7th China Pharmaceutical Innovation and Investment Conference
To promote the integration of social capital with pharmaceutical innovation and enhance pharmaceutical innovation capabilities,3month29day-3month31On the 7th, the 7th China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as the 'Venture Capital Conference') was grandly held by the banks of Jinji Lake in Suzhou. This year's Venture Capital Conference was co-hosted by the China Pharmaceutical Manufacturers Association, Hong Kong Exchanges and Clearing Limited, Aimeida Consulting, and Dingxin Medicine.7Over the past year, the Venture Capital Conference has received strong support from Suzhou Industrial Park and has also attracted high attention and widespread praise from the domestic and international industry and investment communities. It is hailed as the 'most highly regarded pharmaceutical innovation and investment cooperation platform in the Asia-Pacific region'.
This conference focuses on the integration and innovation of the pharmaceutical industry with capital under new circumstances, aiming to stimulate the source technological innovation vitality of China's pharmaceutical innovation entities and to shape a high-quality development pharmaceutical innovation ecological environment.
A total of12Industry-themed forums, as well as8A themed roadshow session featuring over a hundred cutting-edge project roadshows. Additionally, the China Pharmaceutical Innovation and Investment Conference's special exhibition area has invited top domestic clinical research institutions, the most innovative R&D enterprises in China, and local industrial parks dedicated to the development of biomedicine to participate.
Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, Zhu Yi, Senior Consulting Director of the Healthcare Business Unit at Frost & Sullivan's Greater China Region, and Li Qian, Consulting Director of the Healthcare Business Unit at Frost & Sullivan's Greater China Region, jointly attended the 'Capital Market Innovation Services Forum' of the conference. They shared and exchanged views with experts from various listed service institutions on hot topics such as the opportunities and challenges faced by biopharmaceutical companies, the strategic choices for listing biopharmaceutical companies, key areas of focus for listing, and the future development trends of the capital market for the biopharmaceutical industry.
Keynote
Partner and Managing Director, Greater China, Frost & Sullivan fattening
At the conference site, Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, delivered a keynote speech on 'The Current Situation and Development Trends of the Nucleic Acid Drug Market'. According to him, Compared to small molecule drugs and antibody drugs, nucleic acid drugs have the advantages of strong targeting specificity, long-lasting action, simple design, short development cycle, and a rich variety of candidate targets. They are currently one of the most popular new therapies alongside cell and gene therapy.
Mao Hua pointed out that globally, most marketed nucleic acid drugs are used for the treatment of rare diseases and the prevention of COVID-19. With the expansion of indications and the continuous development and improvement of technology platforms, the sales of the vast majority of nucleic acid drugs are currently showing an upward trend. At the same time, multinational pharmaceutical companies have also actively deployed nucleic acid drugs, covering a wide range of disease areas including cardiovascular, hepatitis B, neurological, metabolic, and oncology. In the future, with the continuous maturation and commercial success of related key technologies, driven by policy support, multi-party R&D cooperation, and capital investment, the nucleic acid drug market has great potential.
" The development and maturation of any pharmaceutical market do not happen overnight; the industry's explosion still requires the exploration of major indications. For example, tumors, metabolic diseases, and autoimmunity, we also expect nucleic acid drugs to make breakthroughs in these indications as soon as possible.2021In the yearmRNAThe sale of vaccines has brought about explosive growth to the global nucleic acid drug market. However, against the backdrop of the global relaxation of COVID-19 lockdowns, the nucleic acid drug market urgently needs new growth points. "Texturing is emphasized," said ” Mao Hua.
Subsequently, Mao Hua analyzed small nucleic acid drugs andmRNAR&D progress and future trends of vaccines and drugs. According to a study by Frost & Sullivan, in In the field of small nucleic acid drugs, there are currently127The drug is in clinical andNon-Disclosure AgreementStage, mainly comprisingASOandRNAidrugs, and most are stillIperiod andIIPhase clinical trial stage, Therefore, the development of the small nucleic acid drug market as a whole still faces the test of pharmaceutical efficacy.
Mao Hua said that the indications for small nucleic acid drugs are extensive, currently mainly focusing on anti-tumor, nervous system, cardiovascular and cerebrovascular fields. Moreover, due to the dual characteristics of small nucleic acid drugs, which combine gene modification with traditional drugs, their application prospects in the field of rare diseases are broad. " "In the future, the small nucleic acid drug market will develop towards trends such as technological innovation, expansion of market scale and demand, multi-party collaboration, industrial clusters, and increasingly complete R&D capabilities," said Mao Hua.
AndmRNAIn the fields of vaccines and drugs, data shows that there are currently77The drug is in clinical development, mainly comprisingmRNAvaccines, and most are stillIperiod andIIIn the phase clinical stage, the indications for the investigational products mainly focus on anti-tumor, treatment of infectious diseases, and other areas. In addition, liposomal nanoparticlesLNP) is the most widely used delivery system currently, accounting for aboutmRNApipeline89%.
Mao Hua pointed out that the COVID-19 pandemic has accelerated itmRNAWith the popularization and commercialization of technology, countries have increased their investment inmRNAThe investment in technology has promotedmRNAConstruction and improvement of the technology platform. In the future, as technology applications gradually mature, it is expectedmRNAThe field of vaccines and drug treatments will continue to expand, with a gradually complete R&D system. Efficacy and safety will also be continuously improved, and the industry is expected to achieve synchronous development through cooperation for mutual benefit.
Roundtable Forum
Senior Consulting Director, Healthcare Business Unit, Frost & Sullivan Greater China Zhu Yi (second from the left)
Zhu Yi, Senior Consulting Director of the Healthcare Practice Group at Frost & Sullivan Greater China, participated in a session on 'Capital Winter's Impact on M&A and IPO Destination Selection'.IPO listingPolicy Roundtable Discussion Session Under the chairmanship of Fei Fan, the Audit Services Partner in charge of the Central China region and co-lead partner for Life Sciences and Healthcare in Greater China at EY Hua Ming Accounting Firm, together with Qiu Yumin, a partner at Shangwen Capital, Tang Zhoujun, a partner at Zhong Lun Law Firm, Ji Lihua, the sponsor representative of the Healthcare Industry Department at Huatai United Securities Co., Ltd., and Zhu Bin, a partner at EY Tax and Business Consulting, we discussed the strategic choices for listing biopharmaceutical companies and the key areas of focus for listing.
Zhu Yi said, The choice of listing location should take into account multiple factors such as investors, market environment, and the progress of core products. after2022In the first wave of adjustments in the year, there have been profound changes in market preferences for risk and innovation standards. Biotech companies need to create their own differentiation to remain invincible and have more flexible options in the capital market.
Consulting Director, Healthcare Business Unit, Frost & Sullivan Greater China Li Qian (second from the left)
Li Qian, Consulting Director of the Healthcare Business Unit of Frost & Sullivan Greater China, participated in the roundtable discussion session themed 'Financing Challenges and Valuation of Biotech Companies in the New Environment'. Under the chairmanship of Liang Fangyuan, Deputy Director of the Healthcare Industry Group at Huatai United Securities Investment Banking, together with Zhang Yiqiang, Audit Services Partner at EY Hua Ming Accounting Firm, Gao Xin, Partner at Zhong Lun Law Firm, and Su Hua, Head of the Life Sciences and Healthcare Industry in Greater China at EY Patton & O'Connor, they discussed the current investment and financing trends in the biopharmaceutical industry under the current environment.
Li Qian believes that the valuation decline of biotech companies is not due to a cold winter, but rather a rational return to value.2017Since the reform of the annual review and approval system, innovative biotech companies have emerged in an endless stream. The market is optimistic, but subsequently there has been industry competition and severe homogenization of targets. The development of the industry has always moved from leniency to strictness.2021year,CDEThe promulgation of the 'Guiding Principles for Clinical Research and Development of Antitumor Drugs Oriented towards Clinical Value' has set higher requirements for candidate drugs entering clinical development. It has also brought the market back to an evaluation based on clinical value and patient benefits, squeezing out bubble components. Regarding valuation restoration,BiotechIt is necessary to grasp innovation, patient benefits, market, and profitability, expand the valuation ceiling, be value-oriented, navigate industry cycles, and achieveBiotechtowardsBiopharma companyTransformation.
Exhibition area
Frost & Sullivan has always regarded the global health industry as one of its core areas of focus. With a global perspective, it is committed to providing full life-cycle services for investment and financing stages to enterprises in the healthcare industry. It helps clients accelerate their growth pace, assist them in achieving growth, innovation, and leading benchmarks within their industry. Frost & Sullivan is also considered one of the most powerful, professional, and influential industry research institutions in the sector.
This time, Frost & Sullivan made an appearance at the China Healthcare Innovation & Investment Conference, attracting the attention of many professional audiences and media. In the exhibition area, through various forms such as display boards and brochures, the company's corporate philosophy and business operations were comprehensively introduced to the visiting guests. At the same time, the latest releases of Frost & Sullivan's Healthcare Business Unit in Greater China were showcased. Several industry development blue books, For example,2023China Rare Diseases Industry Trend Observation Report》, Medical DevicesCRO firmIndustry Status Quo and Development Trends Report, Blue Book on the Current Situation and Development Trends of China's Artificial Liver Industry, Report on the Current Situation and Development Trends of the Modified New Drug IndustryCDMO companyResearch Reports on the Current Development Status and Future Trends of the Industry, etc., aiming to provide important reference perspectives for market stakeholders.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences sector. Leveraging the global think tank resources of Frost & Sullivan and its cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in investment and financing services for the healthcare industry. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions, offering one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
